ReVision Optics, Inc. Advances PresbyLens into Phase 3 Clinical Trial for Improving Near Vision in Patients with Presbyopia

6/11/2012 10:14:40 AM

LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens™ into the final phase of its U.S. clinical trial under an Investigational Device Exemption (IDE). PresbyLens is a clear, circular corneal inlay comprised of approximately 80% water and is less than half the thickness of a human hair.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• ReVision Optics, Inc.

• Clinical - Phase III

• Medical Devices

• Medical Dev. & Diag. - Research